In a special feature focused on drug pricing solutions and value, PharmaLive’s Christiane Truelove talks with Precision subject matter experts Jeremy Schafer and Jason Shafrin, who offer their perspectives on the complex landscape.
HHS has proposed a new rule targeting drug rebates given by pharmaceutical manufacturers to sponsors under Medicare Part D, Medicaid MCPs and the PBMs contracting with them. Todd Edgar, Precision for Value Senior Vice President, shares his insights in Radar on Specialty Pharmacy.
To read the full article, please see below
What will the pharma industry see in 2019? Market Access Spotlight asked five industry leaders, including Jeremy Schafer, PharmD, MBA, Senior Vice President of Specialty Solutions at Precision for Value. Answers start with groundbreaking therapies coupled with concerns about pricing and explore the aftermath of mergers and other industry inflection points.
What is the ripple effect of proposed pricing rules in American Patients First? Todd Edgar, Precision for Value Senior Vice President and former top PBM executive, shares his unique insights in Pharmaceutical Commerce. Spoiler: The revision won’t work for everyone.
To read the full article, click here.
New Practice Will Focus on Accelerating Value-Based Programs to Improve Healthcare Delivery and Patient Outcomes
NEW YORK, NY – January 24, 2019 – Precision for Value, part of Precision Value & Health, announced the formation of the Value Transformation Practice, a novel initiative to equip life sciences companies with actionable strategies, solutions, and partnerships to succeed in an increasingly value-based healthcare environment. Leading the new practice and building upon Precision’s commitment to offer its clients the most creative and innovative healthcare solutions, Dr. Maureen Hennessey, PhD, CPCC, CPHQ, has been promoted to Senior Vice President, Director of Value Transformation.
In today’s rapidly evolving healthcare ecosystem, it is imperative for manufacturers to have access to the latest knowledge, tools, and innovations to adapt and thrive in the next generation of value-based care. The Value Transformation Practice will enable Precision’s life sciences clients to be active participants in shaping the changing healthcare landscape and deliver value in today’s currency: better patient experience, lower costs, and improved population health.
Near-term priorities include the implementation of customized education and training programs, quality and population health offerings, and value-based care insights forums. Longer-term, initiatives will address the seismic shifts in healthcare systems and ensure that patients will have access to the latest and most innovative treatments available.
“The adoption of new, innovative therapies often takes too long—spanning years from the start of evidence-based study to full evidence-based practice,” explains Dr. Hennessey. “However, lives are at stake and many patients in need just don’t have that much time. By enhancing customer acumen related to value-based innovation, technology, and expertise, the development and implementation of life-changing therapies can be accelerated to deliver better care. In pursuit of that goal, I’m very excited to lead the Value Transformation Practice and guide our clients towards next-generation strategies and solutions that will lead to multi-dimensional transformations across the entire healthcare delivery system.”
Dr. Hennessey has led the development of more than 500 strategic quality initiatives with 35 clients in 17 therapeutic areas and served as quality management expert for the launching of Precision’s proprietary quality measure navigation and performance aggregation tool, QnavTM. Under Hennessey’s executive leadership, organizations have received recognition from the National Alliance of Healthcare Purchaser Coalitions (formerly the National Business Coalition on Health), the National Committee for Quality Assurance (NCQA), and the National Academy of Medicine (formerly the Institute of Medicine).
“Strategic innovations are critical to who we are as a company,” commented Dan Renick, President of Precision Value & Health. “In her new role at the helm of Precision’s Value Transformation Practice, Maureen is uniquely qualified to be a potent catalyst in assisting current and future biopharmaceutical innovators to develop forward-thinking, value-based programs, and we are excited to be able to apply her decades of experience and leadership to this important endeavor.”
About Precision for Value
Precision for Value supports commercial excellence for global pharmaceutical and life sciences clients through the demonstration and communication of product value and outcomes. The Precision for Value teams provide clients with services grounded in decades of industry knowledge, demonstrated analytics proficiency, and marketing and communications prowess—making Precision for Value the preferred strategic partner in the industry. Precision for Value is part of Precision Value & Health, the leading partner to pharmaceutical and life sciences companies in improving health outcomes by establishing the value of medical innovations and expanding global market access for patients. For more information, please visit: precisionforvalue.com
In a special commentary appearing in STAT News, Jacki Chou, Senior Director, Policy & Economics, and her co-author discuss overcoming 5 critical challenges in the US biosimilars marketplace, offering some strategic policy recommendations for the consideration of key healthcare stakeholders.
Strengthens Precision’s Position as Leading Partner to Pharmaceutical and Life Sciences Companies at All Life Cycle Stages
Bethesda, MD – December 17, 2018 – Precision Medicine Group, LLC. (Precision) today announced it has acquired Stern Investor Relations, Inc. (Stern IR), a leading investor relations firm for entrepreneurial biotechnology and healthcare companies. With this acquisition, Precision significantly expands its capabilities to include a complete range of strategic communication services aimed at facilitating capital formation and enhancing client visibility and productive interactions with the financial community. Stern IR supports more than 70 companies in the entrepreneurial biotechnology and healthcare sectors, and its core competencies include creation of investor relations strategy aimed at lowering the cost of capital, positioning and messaging development, relationship building with the financial community, and seamless tactical execution. (more…)
VETERAN STRATEGIST CHOSEN TO LEAD INNOVATIVE HEALTH ECONOMICS,
MARKET ACCESS, AND PAYER ANALYTICS CONSULTANCY
Bethesda, MD – November 7, 2018 – Precision Xtract, part of Precision Value & Health, today announced Zac Stillerman, acclaimed healthcare industry operator and strategist, as new president and general manager. Responsible for leading Precision Xtract through its next phase of growth, Stillerman has a proven ability to translate vision and strategy into dynamic collaboration and first-class execution. He joins Precision Xtract at a time of growing demand from innovative life sciences companies for essential consulting activities, including health economic outcomes research, value demonstration, pricing and market access, and commercialization.
In an interview with Radar, Specialty Pharmacy News, Precision’s Tricia Garland, Todd Edgar, and Stephanie Kennedy, discuss how payers could be incorporating elements of value frameworks as a part of their decision-making.
On Wednesday, September 26th at 10:00am PDT/1:00pm EDT please join us for a special, live webinar:
Navigating the FDA’s Final Guidance on HCEI and PIE:
Value Communication That Works
Presented by: